APRE
Aprea Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.76
+1.32%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- +15.1%
- EBIT
- +10.6%
- EPS
- +44.4%
- Free cash flow
- +4.4%
- Operating cash flow
- +4.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -30.4%
- EPS
- +76.7%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +2.8%
- EBIT
- +7.6%
- Net income
- +2.8%
- EPS
- +17.9%
- Free cash flow
- +5.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026